Questioning the role of checkpoint kinase 2 in the p53 DNA damage response - PubMed (original) (raw)
. 2003 Jun 6;278(23):20480-9.
doi: 10.1074/jbc.M213185200. Epub 2003 Mar 24.
Affiliations
- PMID: 12654916
- DOI: 10.1074/jbc.M213185200
Free article
Questioning the role of checkpoint kinase 2 in the p53 DNA damage response
Jinwoo Ahn et al. J Biol Chem. 2003.
Free article
Abstract
Cdc25C and p53 have been reported to be physiological targets of checkpoint kinase 2 (Chk2). Surprisingly, although Chk2 purified from DNA damage sustaining cells has dramatically increased ability to phosphorylate Cdc25C when compared with untreated cells, its ability to phosphorylate p53 is weak before treatment, and there is no increase in its activity toward p53 after DNA damage by gamma irradiation or the radiomimetic agent neocarzinostatin. Furthermore, introduction of Chk2 short interfering RNA into three different human tumor cell lines leads to marked reduction of Chk2 protein, but p53 is still stabilized and active after DNA damage. The results with Chk1 short interfering RNA indicate as well that Chk1 does not play a role in human p53 stabilization after DNA damage. Thus, Chk1 and Chk2 are unlikely to be regulators of p53 in at least some human tumor cells. We discuss our results in the context of previous findings demonstrating a requirement for Chk2 in p53 stabilization and activity.
Similar articles
- Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation.
Ahn J, Prives C. Ahn J, et al. J Biol Chem. 2002 Dec 13;277(50):48418-26. doi: 10.1074/jbc.M208321200. Epub 2002 Oct 16. J Biol Chem. 2002. PMID: 12386164 - Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.
Pan Y, Ren KH, He HW, Shao RG. Pan Y, et al. Cancer Biol Ther. 2009 Aug;8(16):1559-66. doi: 10.4161/cbt.8.16.8955. Epub 2009 Aug 8. Cancer Biol Ther. 2009. PMID: 19502782 - Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents.
Damia G, Broggini M. Damia G, et al. Cell Cycle. 2004 Jan;3(1):46-50. Cell Cycle. 2004. PMID: 14657665 Review. - The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability.
Chen Y, Poon RY. Chen Y, et al. Front Biosci. 2008 May 1;13:5016-29. doi: 10.2741/3060. Front Biosci. 2008. PMID: 18508566 Review.
Cited by
- The Role of Nitric Oxide in Cancer: Master Regulator or NOt?
Khan FH, Dervan E, Bhattacharyya DD, McAuliffe JD, Miranda KM, Glynn SA. Khan FH, et al. Int J Mol Sci. 2020 Dec 10;21(24):9393. doi: 10.3390/ijms21249393. Int J Mol Sci. 2020. PMID: 33321789 Free PMC article. Review. - Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.
Massey AJ, Stokes S, Browne H, Foloppe N, Fiumana A, Scrace S, Fallowfield M, Bedford S, Webb P, Baker L, Christie M, Drysdale MJ, Wood M. Massey AJ, et al. Oncotarget. 2015 Nov 3;6(34):35797-812. doi: 10.18632/oncotarget.5929. Oncotarget. 2015. PMID: 26437226 Free PMC article. - Senescence from G2 arrest, revisited.
Gire V, Dulic V. Gire V, et al. Cell Cycle. 2015;14(3):297-304. doi: 10.1080/15384101.2014.1000134. Cell Cycle. 2015. PMID: 25564883 Free PMC article. Review. - Distinct DNA damage determines differential phosphorylation of Chk2.
Ouchi M, Ouchi T. Ouchi M, et al. Cancer Biol Ther. 2014;15(12):1700-4. doi: 10.4161/15384047.2014.972823. Cancer Biol Ther. 2014. PMID: 25535901 Free PMC article. - CHK2 kinase in the DNA damage response and beyond.
Zannini L, Delia D, Buscemi G. Zannini L, et al. J Mol Cell Biol. 2014 Dec;6(6):442-57. doi: 10.1093/jmcb/mju045. Epub 2014 Nov 17. J Mol Cell Biol. 2014. PMID: 25404613 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous